Number of shares and votes in Medivir AB on 30 June 2026

Summary by AI ^BETAClose X

Medivir AB announced a change in its share structure due to a directed share issue to institutional investors, with the first tranche completed and adding 79,268,294 ordinary shares. As of June 30, 2026, the company has a total of 620,389,677 shares, comprising 617,939,514 ordinary shares and 2,450,163 class C-shares, resulting in 618,184,530.3 total votes. The second tranche of the share issue is pending general meeting approval and is expected to finalize by the end of July.

Disclaimer*

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces that the number of shares and votes in Medivir has changed during June 2026, as a result of the directed issue of shares to Swedish and international institutional investors resolved by Medivir on 17 June 2026, as previously announced. The share issue is carried out in two tranches, of which the first tranche has been delivered and completed. The second tranche is conditional upon approval by the general meeting and is expected to be completed by the end of July. The issue has been previously announced through a separate press release. Tranche 1 of the new share issue resulted in an increase in the number of shares in the company by 79,268,294 ordinary shares.

Today, the last trading day of the month, there are in total 620,389,677 shares in Medivir, of which 617,939,514 ordinary shares and 2,450,163 class C-shares, which together carry 618,184,530.3 votes. One ordinary share entitles the holder to one (1) vote and one class C-share entitles the holder to one tenth (1/10) of a vote.

For additional information, please contact:
Jens Lindberg, CEO, Medivir AB
Phone: +46 72 531 11 17
Email: jens.lindberg@medivir.com

About Medivir
Medivir develops innovative therapies targeting diseases with high unmet medical need. The company’s drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calvé-Perthes disease (Perthes disease). Both candidates have blockbuster potential, representing significant value creation opportunities Medivir’s shareholders. Collaborations play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com